Given the close link between MASLD and T2DM, antidiabetic drugs such as glucagon-like peptide 1 (GLP-1) receptor modulators have been employed to prevent MASLD progression, achieving favorable outcomes in both preclinical models and patients cohorts [7,8,9]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.